论文部分内容阅读
东莞氧胺(TMX)为一非固醇类雌激素拮抗剂,广泛用于晚期和复发乳腺癌。TMX使约60％雌激素受体(ER)阳性和10％ER阴性的乳腺癌肿缩小。一些临床试验表明,对ER阳性的绝经后乳腺癌患者TMX可作为一有效辅助治疗。目前尚未阐明在体内TMX治疗对人乳腺癌ER和孕激素受体(PR)水平的影响。在本研究中,作者试图从同一乳腺癌中获得系列细针穿刺吸引(FNA)标本,用酶联免疫法(EIA)检测TMX对人乳腺癌ER水平的影响及对PR的影响。
Oxytoxamine (TMX) is a nonsteroidal estrogen antagonist widely used in advanced and recurrent breast cancers. TMX reduces approximately 60% of estrogen receptor (ER) positive and 10% ER negative breast cancer. Some clinical trials have shown that TMX in postmenopausal breast cancer patients with ER positive can be used as an effective adjuvant therapy. The effect of TMX therapy in vivo on ER and progesterone receptor (PR) levels in human breast cancer has not yet been elucidated. In this study, the authors attempted to obtain a series of fine needle aspiration (FNA) specimens from the same breast cancer. The effect of TMX on the ER level of human breast cancer and the effect of PR were detected by enzyme-linked immunosorbent assay (EIA).